Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating expenses:    
Research and development $ 35,882 $ 83,837
General and administrative 17,425 19,238
Restructuring (benefit) charges (705) 5,075
Total operating expenses 52,602 108,150
Loss from operations (52,602) (108,150)
Other income:    
Interest income 1,616 5,342
Total other income 1,616 5,342
Net loss (50,986) (102,808)
Other comprehensive (loss) income:    
Unrealized (loss) gain on marketable securities (72) 138
Total other comprehensive (loss) income (72) 138
Comprehensive loss $ (51,058) $ (102,670)
Basic and diluted net loss per common share $ (0.74) $ (1.53)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share 68,893,127 67,033,046